article
Scientific workflow for hypothesis testing in drug discovery: Part 1 of 3
Explore the step-by-step scientific workflow behind drug discovery, from formulating hypotheses to analysing data, ensuring accurate and reliable results.
List view / Grid view
Targets
news
FDA greenlights AI-developed drug targeting solid tumors
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
news
CNIC identifies key mechanism in fat cells to combat obesity
CNIC researchers have identified a mechanism in fat cells that helps them safely store excess fat, offering new insights for combating obesity and related metabolic diseases.
article
The paradox of data in precision medicine
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
news
Breakthrough trial offers new hope for cystic fibrosis patients
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
article
Beyond ELISA: the future of biomarker validation
The era of precision medicine demands more rigorous biomarker validation methods. While ELISA has long been the gold standard, advanced technologies such as LC-MS/MS and Meso Scale Discovery (MSD) offer superior precision, sensitivity and efficiency. Here, Prasad Lakshmanan Selvaraj, Director of Technical Review at Sannova, explains that by embracing these…
news
Blood-brain barrier breakthrough for ALS and Alzheimer’s disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
article
Biotech leader champions targeted cancer treatments and diversity
Driven by a passion for innovation and inclusivity, Dr Catherine Pickering, CEO of iOnctura, is on a mission to transform cancer treatment while championing diversity within the biotech industry.
article
Targeting CD40 with bispecifics to outsmart tumours
Søren Bregenholt, Chief Executive Officer at Alligator Bioscience, elucidates how creating bispecific antibodies that target both tumour-specific antigens and CD40, a receptor on the immune system’s dendritic cells, is a new approach that aims to trick tumours into telling the immune system how best to attack.
article
Leveraging agonist antibodies to address immunological diseases
Therapeutic antibodies play a key role in addressing unmet medical needs. Here, Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases, helping to mediate interactions between circulating immune cells and influencing the intensity and…
article
The essential role of recombinant phage display antibody libraries
The emergence of new antibody-based therapeutics, such as antibody-drug conjugates, alongside a continued drive towards alternatives to animal testing approaches, highlights the need for precise and sensitive tools enabling the identification and characterisation of the best drug candidates for clinical progression. Capable of keeping up with the evolving drug development…
news
Carbonic anhydrase inhibitors protect against tau protein build-up
The glaucoma drug methazolamide removed tau build-up and lessened signs of dementia in genetically-engineered zebrafish and mice.
article
Chemical choreography: orchestrating complex API syntheses
Small molecules are essential for developing effective medicines, but their structural complexity and material behaviour present difficulties. In this article, Chris Brown, Senior Chemist, Onyx Scientific Ltd, discusses how the right technologies and approaches can enhance drug development and mitigate risk from initial phase to commercial launch.
news
INPP4B exerts its tumour-promoting effects via lysosomes
Researchers have uncovered a how INPP4B, alongside PIKfyve and TRPML-1, drives pancreatic cancer metastasis.
news
New AI model may enable more targeted prostate cancer treatment
Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.